Porous yolk-shell Fe/Fe3O4 nanoparticles with controlled exposure of highly active Fe(0) for cancer therapy
Porous yolk-shell Fe/Fe3O4 nanoparticles with controlled exposure of highly active Fe(0) for cancer therapy
复制标题
DOI：
10.1016/j.biomaterials.2020.120530
复制
发表时间：
2021-01-01
期刊：
影响因子：
14
通讯作者：
Sun, Xiaolian
中科院分区：
文献类型：
--
作者：
Liang, Huan;Guo, Jingru;Sun, Xiaolian
基于铁的芬顿型反应在癌症治疗中引起了极大的关注。与氧化铁相比，Fe（0）具有较高的催化活性，但在生物医学应用中不稳定。在这里，我们报告了一种新的策略，通过Fe/Fe 3 O 4（PYSNPs）的多孔蛋黄壳纳米结构在正常生理条件下稳定Fe（0），并控制Fe（0）在肿瘤微环境中的释放，以增强癌症治疗。这些PYSNPs显示出对HepG 2细胞的上级肿瘤抑制作用，IC 50低至20 μ g/mL（对于作为对照的氧化铁纳米颗粒，IC 50超过1 mg/mL）。低至1 mg/kg剂量的单次静脉注射可有效抑制体内肿瘤生长。此外，PYSNPs在酸性肿瘤微环境中的分解可引起MRI信号的显著变化，用于对比增强诊断。值得注意的是，所得的Fe 3 O 4碎片是肾可清除的，副作用最小。总之，这项工作代表了一种纳米平台，可以稳定和选择性地递送Fe（0），用于高效的癌症治疗。
The iron-based Fenton-type reaction has drawn tremendous attention in cancer therapy. Compared with oxidized iron, Fe(0) possesses high catalytic activity but unstable for biomedical application. Here, we report a new strategy to stabilize Fe(0) via a porous yolk shell nanostructure of Fe/Fe3O4 (PYSNPs) in normal physiological condition, and to control the release of Fe(0) in tumor microenvironment for enhanced cancer therapy. These PYSNPs display superior tumor inhibition with the IC50 down to 20 mu g/mL (over 1 mg/mL for iron oxide nanoparticles as control) for HepG2 cell. A single intravenous injection of as low as 1 mg/kg dosage is effective to suppress tumor growth in vivo. Moreover, the disintegration of PYSNPs in the acidic tumor microenvironment could cause significant change in MRI signal for contrast-enhanced diagnosis. Of note, the resulting Fe3O4 fragments are renal clearable with minimized side effect. In all, this work represented a nanoplatform to stabilize and selectively deliver Fe(0) for highly effective cancer therapy.